Vobramitamab duocarmazine
As of the edition of 20 October 2026, Vobramitamab duocarmazine is an antibody drug conjugate: stopped in 2025; acts on CD276.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2025
- Kind
- Antibody drug conjugate
- Registered trials
- 4, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Skin and connective tissue; Digestive system; Urinary and reproductive; Hormones
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Vobramitamab duocarmazine.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD276 | CD276 antigen | Q5ZPR3 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 3 | 0 | 1 | 2 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| MacroGenics | Lead sponsor of trials | 2018 to now |